The chemist, the lawyer and the baker

In the fourth video of our Creative Law Series we talk with Hiroshi Sheraton about the impact of the patent cliff on the pharmaceutical industry. The traditional model of drugs development is changing as the industry embraces increased collaboration with academics, smaller companies and open innovation. Against this backdrop, the historical role of the generics manufacturer is itself changing.

In the context of litigation costs we discuss whether this landscape will result in more or less litigation and the impact of the development of the Single European patent and the new Intellectual Property Enterprise Court.

Tune-in to Hiroshi and the Creative Law Series here.

Area of Interest